Clay Thorp Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Clay Thorp.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Clay Thorp. Clay Thorp is Director in PhaseBio Pharmaceuticals Inc ($PHAS) and Director in Clearside Biomedical, Inc. ($CLSD) and 10% Owner in G1 Therapeutics, Inc. ($GTHX).
Latest Insider Trading Transactions of Clay Thorp
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, CLSD, GTHX, PHAS
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 04 2021 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | A | 3.53 | 14,000 | 49,420 | 14,000 | |
Feb 12 2021 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 4.43 | 32,873 | 145,627 | 3,433,521 | 3.5 M to 3.4 M (-0.95 %) |
Jun 19 2020 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Option Exercise | A | 2.00 | 25,000 | 50,000 | 25,000 | |
Jun 05 2020 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | A | 4.86 | 16,000 | 77,760 | 16,000 | |
Nov 26 2019 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Grant | A | 1.05 | 1,518,026 | 1,599,999 | 4,984,420 | 3.5 M to 5 M (+43.79 %) |
Jul 03 2019 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Sell | S | 14.00 | 459 | 6,426 | 415,959 | 416.4 K to 416 K (-0.11 %) |
Jul 03 2019 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Sell | S | 14.00 | 255 | 3,570 | 52,397 | 52.7 K to 52.4 K (-0.48 %) |
Jul 03 2019 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Sell | S | 14.00 | 180 | 2,520 | 162,890 | 163.1 K to 162.9 K (-0.11 %) |
Jul 03 2019 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Sell | S | 14.00 | 2,014 | 28,196 | 1,818,638 | 1.8 M to 1.8 M (-0.11 %) |
Jun 24 2019 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Option Exercise | A | 1.07 | 20,000 | 21,400 | 20,000 | |
Jun 20 2019 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Sell | S | 14.00 | 63 | 882 | 416,418 | 416.5 K to 416.4 K (-0.02 %) |
Jun 20 2019 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Sell | S | 14.00 | 35 | 490 | 52,655 | 52.7 K to 52.7 K (-0.07 %) |
Jun 20 2019 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Sell | S | 14.00 | 25 | 350 | 163,074 | 163.1 K to 163.1 K (-0.02 %) |
Jun 20 2019 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Sell | S | 14.00 | 277 | 3,878 | 1,820,656 | 1.8 M to 1.8 M (-0.02 %) |
May 13 2019 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | A | 13.23 | 11,000 | 145,530 | 11,000 | |
Mar 01 2019 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | A | 3.15 | 36,000 | 113,400 | 36,000 | |
Dec 06 2018 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Buy | P | 1.36 | 8,000 | 10,880 | 8,000 | 0 to 8 K |
Dec 06 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Buy | P | 3.13 | 4,000 | 12,520 | 15,799 | 11.8 K to 15.8 K (+33.90 %) |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | C | 0.00 | 226,061 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | C | 0.00 | 24,709 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | C | 0.00 | 272,107 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | C | 0.00 | 40,420 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | C | 0.00 | 13,558 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | C | 0.00 | 149,320 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | C | 0.00 | 94,874 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | C | 0.00 | 1,044,764 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | C | 0.00 | 13,609 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | C | 0.00 | 174,699 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | C | 0.00 | 4,846 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | C | 0.00 | 3,862 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | C | 0.00 | 42,530 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | C | 0.00 | 52,690 | 0 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | S | 0.00 | 994 | 0 | 40,420 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | M | 0.00 | 41,414 | 0 | 41,414 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | M | 0.12 | 41,414 | 4,970 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | S | 0.00 | 104 | 0 | 13,558 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | M | 0.00 | 4,309 | 0 | 13,662 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | M | 0.12 | 4,309 | 517 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | S | 0.00 | 1,139 | 0 | 149,320 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | M | 0.00 | 47,458 | 0 | 150,459 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | M | 0.12 | 47,458 | 5,695 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | S | 0.00 | 42 | 0 | 94,874 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | M | 0.00 | 1,731 | 0 | 94,916 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | M | 0.12 | 1,731 | 208 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | S | 0.00 | 458 | 0 | 1,044,764 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | M | 0.00 | 19,061 | 0 | 1,045,222 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | M | 0.12 | 19,061 | 2,287 | 0 | |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Buy | P | 5.00 | 150,000 | 750,000 | 416,481 | 266.5 K to 416.5 K (+56.29 %) |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Buy | C | 0.00 | 266,481 | 0 | 266,481 | 0 to 266.5 K |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Buy | C | 0.00 | 4,846 | 0 | 4,846 | 0 to 4.8 K |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Buy | P | 5.00 | 12,487 | 62,435 | 163,099 | 150.6 K to 163.1 K (+8.29 %) |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Buy | C | 0.00 | 150,612 | 0 | 150,612 | 0 to 150.6 K |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Buy | P | 5.00 | 137,513 | 687,565 | 1,820,933 | 1.7 M to 1.8 M (+8.17 %) |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Buy | C | 0.00 | 1,683,420 | 0 | 1,683,420 | 0 to 1.7 M |
Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Buy | C | 0.00 | 52,690 | 0 | 52,690 | 0 to 52.7 K |
Jun 21 2018 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Option Exercise | A | 10.74 | 11,250 | 120,825 | 11,250 | |
Jun 01 2018 | GTHX | G1 Therapeutics, I ... | Thorp Clay | 10% Owner | Sell | S | 48.00 | 41,710 | 2,002,080 | 3,237,711 | 3.3 M to 3.2 M (-1.27 %) |
Jun 01 2018 | GTHX | G1 Therapeutics, I ... | Thorp Clay | 10% Owner | Sell | S | 48.00 | 758,290 | 36,397,920 | 3,279,421 | 4 M to 3.3 M (-18.78 %) |
May 23 2018 | GTHX | G1 Therapeutics, I ... | Thorp Clay | 10% Owner | Sell | S | 50.50 | 26 | 1,313 | 4,037,711 | 4 M to 4 M (0.00 %) |
May 23 2018 | GTHX | G1 Therapeutics, I ... | Thorp Clay | 10% Owner | Sell | S | 50.50 | 474 | 23,937 | 4,037,737 | 4 M to 4 M (-0.01 %) |
May 23 2018 | GTHX | G1 Therapeutics, I ... | Thorp Clay | 10% Owner | Sell | S | 50.69 | 308 | 15,611 | 4,038,211 | 4 M to 4 M (-0.01 %) |
May 23 2018 | GTHX | G1 Therapeutics, I ... | Thorp Clay | 10% Owner | Sell | S | 50.86 | 5,592 | 284,405 | 4,038,519 | 4 M to 4 M (-0.14 %) |
May 23 2018 | GTHX | G1 Therapeutics, I ... | Thorp Clay | 10% Owner | Sell | S | 52.13 | 26 | 1,355 | 4,044,111 | 4 M to 4 M (0.00 %) |
May 23 2018 | GTHX | G1 Therapeutics, I ... | Thorp Clay | 10% Owner | Sell | S | 52.13 | 474 | 24,710 | 4,044,137 | 4 M to 4 M (-0.01 %) |
May 23 2018 | GTHX | G1 Therapeutics, I ... | Thorp Clay | 10% Owner | Sell | S | 51.06 | 1,595 | 81,439 | 4,044,611 | 4 M to 4 M (-0.04 %) |
May 23 2018 | GTHX | G1 Therapeutics, I ... | Thorp Clay | 10% Owner | Sell | S | 51.16 | 29,005 | 1,483,907 | 4,046,206 | 4.1 M to 4 M (-0.71 %) |
May 21 2018 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 13.16 | 61,139 | 804,589 | 3,466,394 | 3.5 M to 3.5 M (-1.73 %) |
May 21 2018 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 13.03 | 100,000 | 1,303,000 | 3,527,533 | 3.6 M to 3.5 M (-2.76 %) |
Mar 23 2018 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 12.02 | 5,231 | 62,877 | 3,627,533 | 3.6 M to 3.6 M (-0.14 %) |
Mar 23 2018 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 12.02 | 5,231 | 62,877 | 3,627,533 | 3.6 M to 3.6 M (-0.14 %) |
Mar 23 2018 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 12.07 | 33,630 | 405,914 | 3,632,764 | 3.7 M to 3.6 M (-0.92 %) |
Mar 23 2018 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 12.07 | 33,630 | 405,914 | 3,632,764 | 3.7 M to 3.6 M (-0.92 %) |
Mar 23 2018 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 12.27 | 100,000 | 1,227,000 | 3,666,394 | 3.8 M to 3.7 M (-2.66 %) |
Mar 23 2018 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 12.27 | 100,000 | 1,227,000 | 3,666,394 | 3.8 M to 3.7 M (-2.66 %) |
Dec 07 2017 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 6.13 | 5,000 | 30,650 | 3,766,394 | 3.8 M to 3.8 M (-0.13 %) |
Dec 07 2017 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 6.09 | 15,000 | 91,350 | 3,771,394 | 3.8 M to 3.8 M (-0.40 %) |
Dec 07 2017 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 6.37 | 15,000 | 95,550 | 3,786,394 | 3.8 M to 3.8 M (-0.39 %) |
Dec 04 2017 | GTHX | G1 Therapeutics, I ... | Thorp Clay | 10% Owner | Buy | J | 0.00 | 995 | 0 | 4,075,211 | 4.1 M to 4.1 M (+0.02 %) |
Dec 04 2017 | GTHX | G1 Therapeutics, I ... | Thorp Clay | 10% Owner | Sell | J | 0.00 | 99,513 | 0 | 4,074,216 | 4.2 M to 4.1 M (-2.38 %) |
Nov 16 2017 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 6.99 | 5,000 | 34,950 | 3,801,394 | 3.8 M to 3.8 M (-0.13 %) |
Nov 16 2017 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 6.99 | 15,000 | 104,850 | 3,806,394 | 3.8 M to 3.8 M (-0.39 %) |
Nov 16 2017 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 7.02 | 15,000 | 105,300 | 3,821,394 | 3.8 M to 3.8 M (-0.39 %) |
Oct 05 2017 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 8.34 | 6,000 | 50,040 | 3,836,394 | 3.8 M to 3.8 M (-0.16 %) |
Oct 05 2017 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 8.59 | 14,000 | 120,260 | 3,842,394 | 3.9 M to 3.8 M (-0.36 %) |
Oct 05 2017 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 8.64 | 15,000 | 129,600 | 3,856,394 | 3.9 M to 3.9 M (-0.39 %) |
Sep 15 2017 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 7.54 | 10,000 | 75,400 | 3,871,394 | 3.9 M to 3.9 M (-0.26 %) |
Sep 15 2017 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 7.52 | 6,000 | 45,120 | 3,881,394 | 3.9 M to 3.9 M (-0.15 %) |
Sep 15 2017 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 7.49 | 8,500 | 63,665 | 3,887,394 | 3.9 M to 3.9 M (-0.22 %) |
Aug 09 2017 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 7.30 | 15,000 | 109,500 | 3,895,894 | 3.9 M to 3.9 M (-0.38 %) |
Aug 09 2017 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 7.98 | 5,000 | 39,900 | 3,910,894 | 3.9 M to 3.9 M (-0.13 %) |
Aug 09 2017 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 8.02 | 4,500 | 36,090 | 3,915,894 | 3.9 M to 3.9 M (-0.11 %) |
Jun 23 2017 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Option Exercise | A | 8.81 | 8,618 | 75,925 | 8,618 | |
May 24 2017 | GTHX | G1 Therapeutics, I ... | Thorp Clay | 10% Owner | Option Exercise | C | 0.00 | 1,009,693 | 0 | 0 | |
May 24 2017 | GTHX | G1 Therapeutics, I ... | Thorp Clay | 10% Owner | Option Exercise | C | 0.00 | 2,584,959 | 0 | 0 | |
May 24 2017 | GTHX | G1 Therapeutics, I ... | Thorp Clay | 10% Owner | Option Exercise | C | 0.00 | 6,568,527 | 0 | 0 | |
May 24 2017 | GTHX | G1 Therapeutics, I ... | Thorp Clay | 10% Owner | Option Exercise | C | 0.00 | 1,318,681 | 0 | 0 | |
May 24 2017 | GTHX | G1 Therapeutics, I ... | Thorp Clay | 10% Owner | Buy | P | 15.00 | 133,333 | 1,999,995 | 3,861,797 | 3.7 M to 3.9 M (+3.58 %) |
May 24 2017 | GTHX | G1 Therapeutics, I ... | Thorp Clay | 10% Owner | Buy | C | 0.00 | 99,513 | 0 | 99,513 | 0 to 99.5 K |
May 24 2017 | GTHX | G1 Therapeutics, I ... | Thorp Clay | 10% Owner | Buy | C | 0.00 | 212,419 | 0 | 212,419 | 0 to 212.4 K |
May 24 2017 | GTHX | G1 Therapeutics, I ... | Thorp Clay | 10% Owner | Buy | C | 0.00 | 3,728,464 | 0 | 3,728,464 | 0 to 3.7 M |
May 19 2017 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 8.31 | 15,000 | 124,650 | 3,920,394 | 3.9 M to 3.9 M (-0.38 %) |
May 19 2017 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 8.44 | 9,000 | 75,960 | 3,935,394 | 3.9 M to 3.9 M (-0.23 %) |
May 17 2017 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 8.39 | 19,000 | 159,410 | 3,944,394 | 4 M to 3.9 M (-0.48 %) |
May 17 2017 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 8.61 | 9,544 | 82,174 | 3,963,394 | 4 M to 4 M (-0.24 %) |
May 17 2017 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 8.94 | 15,941 | 142,513 | 3,972,938 | 4 M to 4 M (-0.40 %) |
Apr 19 2017 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 7.37 | 2,030 | 14,961 | 3,988,879 | 4 M to 4 M (-0.05 %) |
Apr 19 2017 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 7.48 | 44,455 | 332,523 | 3,990,909 | 4 M to 4 M (-1.10 %) |
Apr 19 2017 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 7.43 | 22,000 | 163,460 | 4,035,364 | 4.1 M to 4 M (-0.54 %) |
Mar 17 2017 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 6.77 | 21,485 | 145,453 | 4,057,364 | 4.1 M to 4.1 M (-0.53 %) |
Mar 17 2017 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 6.47 | 47,000 | 304,090 | 4,078,849 | 4.1 M to 4.1 M (-1.14 %) |
Feb 17 2017 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 7.54 | 10,000 | 75,400 | 4,152,849 | 4.2 M to 4.2 M (-0.24 %) |
Feb 17 2017 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 7.58 | 14,000 | 106,120 | 4,162,849 | 4.2 M to 4.2 M (-0.34 %) |
Feb 17 2017 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 7.64 | 17,485 | 133,585 | 4,176,849 | 4.2 M to 4.2 M (-0.42 %) |
Jan 20 2017 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 7.77 | 8,000 | 62,160 | 4,194,334 | 4.2 M to 4.2 M (-0.19 %) |
Jan 20 2017 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 8.23 | 15,485 | 127,442 | 4,202,334 | 4.2 M to 4.2 M (-0.37 %) |
Jan 20 2017 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 8.64 | 25,000 | 216,000 | 4,217,819 | 4.2 M to 4.2 M (-0.59 %) |
Jan 20 2017 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 8.92 | 20,000 | 178,400 | 4,242,819 | 4.3 M to 4.2 M (-0.47 %) |
Jun 07 2016 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Option Exercise | X | 0.02 | 21,705 | 478 | 0 | |
Jun 07 2016 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Option Exercise | X | 0.02 | 1,805 | 40 | 0 | |
Jun 07 2016 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Option Exercise | X | 0.02 | 19,900 | 438 | 0 | |
Jun 07 2016 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Option Exercise | C | 0.00 | 675,795 | 0 | 0 | |
Jun 07 2016 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Option Exercise | C | 0.00 | 865,881 | 0 | 0 | |
Jun 07 2016 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Option Exercise | C | 0.00 | 1,654,531 | 0 | 0 | |
Jun 07 2016 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Option Exercise | C | 0.00 | 4,071,815 | 0 | 0 | |
Jun 07 2016 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Buy | P | 7.00 | 785,714 | 5,499,998 | 4,262,819 | 3.5 M to 4.3 M (+22.60 %) |
Jun 07 2016 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Sell | S | 7.00 | 138 | 966 | 3,477,105 | 3.5 M to 3.5 M (0.00 %) |
Jun 07 2016 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Buy | X | 0.02 | 43,410 | 955 | 3,477,243 | 3.4 M to 3.5 M (+1.26 %) |
Jun 07 2016 | CLSD | Clearside Biomedic ... | Thorp Clay | Director | Buy | C | 0.00 | 3,321,785 | 0 | 3,433,833 | 112 K to 3.4 M (+2,964.61 %) |
Page: 1